Bagsværd,
In the third quarter of 2020, Novo Nordisk’s sales increased by 7% and operating profit increased by 7%, both at CER. This reflects lower than anticipated negative impacts from COVID-19 as well as underlying market demand. Sales growth was positively impacted by inventory changes at wholesaler level in the US.
Profit and Loss (CER) | First nine months 2020 | Third quarter 2020 |
Net sales growth | 7% | 7% |
Operating profit growth | 7% | 7% |
Following lower than anticipated negative COVID-19 impacts and underlying market demand, full-year outlook is increased for sales and operating profit, both at CER.
Outlook 2020 (CER) | Expectations 8 October | Expectations 6 August |
Sales growth | 5-8% | 3-6% |
Operating profit growth | 5-8% | 2-5% |
Novo Nordisk’s full disclosure of the financial results for the first nine months of 2020 will be published on
The outlook is based on a number of assumptions related to the severity and duration of impacts from COVID-19. In addition, the above expectations are based on assumptions which are further described on pages 15 and 16 of the Financial Report for the period
The forward-looking statements on page 21 of the Financial Report for the period
Conference call to be held on
On
Further information
Media: | ||
+45 3079 3883 | mkd@novonordisk.com | |
+1 609 240 9429 | kiau@novonordisk.com | |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
+45 3079 0301 | jvls@novonordisk.com | |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
+45 3079 4211 | mjhr@novonordisk.com | |
+1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 58 / 2020
Attachment
- PR201008_Guidance_update
© OMX, source